How do cannabinoids block pain signals at the nerve level?
Cannabinoids can directly interfere with the electrical machinery that nerves use to send pain signals. A key target is the Nav1.8 sodium channel, a protein found only in peripheral pain-sensing neurons that is essential for repetitive firing of pain signals. A 2025 study found that three non-psychoactive cannabinoids—cannabidiol (CBD), cannabigerol (CBG), and cannabinol (CBN)—effectively inhibit this channel, with CBG showing the strongest effect at reducing the excitability of sensory neurons [1]. This means that even without activating the classic 'high' receptors, these compounds can physically block the nerve's ability to transmit pain impulses.
This mechanism is especially important because Nav1.8 has been clinically validated as a pain target: recent human trials have shown that blocking this channel alone can reduce pain [1]. By targeting the same channel, cannabinoids offer a non-addictive, non-psychoactive way to achieve a similar effect.
How do cannabinoids reduce inflammatory pain?
Beyond blocking nerve signals, cannabinoids also reduce pain by calming the inflammatory environment that sensitizes nerves. A 2023 study on chronic pelvic pain showed that CBD, cannabichromene (CBC), and CBG each significantly reduced inflammation in prostate cells by blocking the TLR4-NFκB signaling pathway—a master switch for inflammation [4]. This led to a marked drop in cyclooxygenase-2 (COX-2), an enzyme that produces pain-promoting molecules. In the same study, CBD-treated rats showed measurable reductions in pain sensitivity compared to placebo [4].
This anti-inflammatory action is separate from the direct nerve-blocking effect, meaning cannabinoids can tackle pain from two angles at once. The endocannabinoid system itself is a natural regulator of inflammation: a 2022 review explains that the body's own endocannabinoids (like anandamide and 2-AG) are produced 'on demand' to dampen pain and inflammation, and that drugs which prevent their breakdown can raise their levels to provide relief [3]. In a migraine model, a dual inhibitor that raised both anandamide and 2-AG levels reduced pain-related behavior by over 50% and lowered levels of the pain peptide CGRP in the blood and spinal cord [5].
What does this mean for practical pain relief?
The evidence points to cannabinoids as versatile pain relievers that work through multiple, complementary mechanisms. However, the translation from lab to clinic is still a work in progress. A 2021 review from the International Association for the Study of Pain concluded that while animal studies strongly support cannabinoids' potential, moving these findings into effective, safe medicines for humans remains a major challenge [2]. The same review notes that the endocannabinoid system is deeply involved in regulating pain, reward, anxiety, and inflammation—which means cannabinoids can have broad effects, both beneficial and unwanted [6].
The key takeaway is that cannabinoids are not a single 'magic bullet' but a class of compounds with different strengths. For example, CBG appears especially promising for blocking nerve pain via Nav1.8 [1], while CBD may be better suited for inflammatory pain via the TLR4 pathway [4]. The most effective approach may eventually combine these compounds or pair them with drugs that boost the body's own endocannabinoids [3][5]. For now, the science strongly supports that cannabinoids can interrupt pain signaling at multiple points, but the best formulation, dose, and route for each type of pain are still being worked out.
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2021 to 2025, 1 from 2024 or later, 5 in Q1 journals, collectively cited 315 times — selected as the most relevant from 7 studies that passed quality screening, drawn from 51 papers retrieved from a database of over 500 million.
Sources used in this answer
Nav1.8, an analgesic target for nonpsychotomimetic phytocannabinoids
This 2025 study shows that non-psychoactive cannabinoids CBD, CBG, and CBN inhibit the Nav1.8 sodium channel in peripheral sensory neurons, with CBG being the most effective at reducing nerve excitability, suggesting a non-opioid mechanism for pain relief.
Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies
This 2021 narrative review from the IASP task force concludes that animal model evidence strongly supports cannabinoids and endocannabinoid system modulators as promising for analgesic drug development, but notes significant challenges in translating this to human medicines.
Inhibiting Endocannabinoid Hydrolysis as Emerging Analgesic Strategy Targeting a Spectrum of Ion Channels Implicated in Migraine Pain
This 2022 review discusses how inhibiting the enzymes MAGL and FAAH raises levels of endocannabinoids like 2-AG and anandamide, which can then modulate ion channels and cannabinoid receptors to alleviate migraine pain.
MP15-08 CANNABINOIDS REDUCE CHRONIC PROSTATITIS AND CHRONIC PELVIC PAIN SYNDROME BY MODULATING TLR-4/NF-KB SIGNALING PATHWAY
This 2023 study on chronic pelvic pain found that CBD, CBC, and CBG reduced inflammation in prostate cells by blocking the TLR4-NFκB pathway, lowering COX-2 levels, and that CBD reduced pain sensitivity in rats.
Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine
This 2021 animal study found that a dual FAAH/MAGL inhibitor (JZL195) reduced migraine-like pain and hyperalgesia in rats, lowering CGRP levels in blood and spinal cord, likely via CB1 receptor activation.
Endocannabinoid signaling in the central nervous system
This 2022 review describes how endocannabinoid signaling (ECS) regulates brain functions including pain, reward, anxiety, and inflammation, with CB1 receptors widely expressed in the CNS and CB2 receptors affecting inflammatory state.